Tagged with S

Taiwan Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho, Superintendent and Professor of Neurosurgery, explains how the institution operates as an integrated innovation platform, advancing cell and gene therapies,…

MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…

USA Tanya Carro details Duchesnay Pharmaceutical Group’s organic expansion from its women’s health core into rare diseases and generics. Operating across three geographic pillars, the privately held firm leverages Canadian pricing discipline and US entrepreneurial agility. Carro emphasizes navigating complex reimbursement landscapes through holistic patient support and securing global supply chains…

Global Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World Evidence is providing the definitive proof that prevention is now an economic and medical necessity.   For decades, the guiding…

Taiwan Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for Biotechnology explain how policy, data, manufacturing discipline, and clinical capability are being aligned to create a coherent national ecosystem. The…

Taiwan Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she has helped position Taiwan as a priority market within the company’s Asia-Pacific region. In this interview, she discusses the rollout…

Hong Kong Professor Chak-sing Lau, BBS, JP, is Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong (HKU). He leads HKU’s Li Ka Shing Faculty of Medicine (HKUMed), one of Asia’s highest-ranked medical schools. Professor Lau discusses the faculty’s evolution into a multidisciplinary health sciences hub, Hong…

USA William Hait, Chief Scientific Advisor of the American Association for Cancer Research (AACR) and Chair of AACR’s Scientific Advisory Council, highlights the society’s position within the global oncology ecosystem as a trusted, unbiased leader facilitating progress from discovery to community impact. Hait details AACR’s focus on prioritizing prevention, early detection,…

USA Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor efficacy through combination therapy, validate science through partnerships with leading institutions, and accelerate timelines to potential regulatory approval. Bedu‑Addo goes…

USA Katherine Stueland, CEO of GeneDx, describes transforming the 26-year-old NIH spinout into a scalable, patient-focused business. Leveraging the Infinity database, strategic biopharma partnerships, AI-driven interpretation, and cost-efficient exome and genome testing, GeneDx accelerates rare disease diagnosis. The company is aiming to assist in the expansion of newborn screening programs as…

USA Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought both CGT manufacturing and established GMP biosafety testing capabilities. Today, Minaris operates under private equity as two complementary businesses: Minaris…

Hong Kong Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He traces the organisation’s evolution from US-based acquisitions to a protein/peptide and circular RNA vaccine platform built in Hong Kong, explains…